Logo image of TRIB

TRINITY BIOTECH PLC-SPON ADR (TRIB) Stock Fundamental Analysis

NASDAQ:TRIB - Nasdaq - US8964385046 - ADR - Currency: USD

0.708  +0.07 (+10.61%)

After market: 0.72 +0.01 (+1.69%)

Fundamental Rating

1

TRIB gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TRIB have multiple concerns. TRIB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year TRIB has reported negative net income.
In the past year TRIB has reported a negative cash flow from operations.
In the past 5 years TRIB reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: TRIB reported negative operating cash flow in multiple years.
TRIB Yearly Net Income VS EBIT VS OCF VS FCFTRIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M -40M -60M -80M -100M

1.2 Ratios

TRIB has a Return On Assets of -20.87%. This is comparable to the rest of the industry: TRIB outperforms 51.83% of its industry peers.
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROIC N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TRIB Yearly ROA, ROE, ROICTRIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K 1.5K

1.3 Margins

TRIB's Gross Margin of 35.74% is on the low side compared to the rest of the industry. TRIB is outperformed by 71.20% of its industry peers.
TRIB's Gross Margin has declined in the last couple of years.
TRIB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 35.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
TRIB Yearly Profit, Operating, Gross MarginsTRIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100

1

2. Health

2.1 Basic Checks

TRIB does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TRIB has less shares outstanding
Compared to 5 years ago, TRIB has more shares outstanding
The debt/assets ratio for TRIB is higher compared to a year ago.
TRIB Yearly Shares OutstandingTRIB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M
TRIB Yearly Total Debt VS Total AssetsTRIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.43, we must say that TRIB is in the distress zone and has some risk of bankruptcy.
TRIB's Altman-Z score of -0.43 is in line compared to the rest of the industry. TRIB outperforms 42.41% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -0.43
ROIC/WACCN/A
WACC9.61%
TRIB Yearly LT Debt VS Equity VS FCFTRIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M

2.3 Liquidity

TRIB has a Current Ratio of 1.64. This is a normal value and indicates that TRIB is financially healthy and should not expect problems in meeting its short term obligations.
TRIB's Current ratio of 1.64 is on the low side compared to the rest of the industry. TRIB is outperformed by 72.77% of its industry peers.
A Quick Ratio of 0.87 indicates that TRIB may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.87, TRIB is doing worse than 82.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.64
Quick Ratio 0.87
TRIB Yearly Current Assets VS Current LiabilitesTRIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

3

3. Growth

3.1 Past

TRIB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.11%, which is quite impressive.
TRIB shows a decrease in Revenue. In the last year, the revenue decreased by -0.01%.
Measured over the past years, TRIB shows a very negative growth in Revenue. The Revenue has been decreasing by -10.15% on average per year.
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%

3.2 Future

TRIB is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.36% yearly.
TRIB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.95% yearly.
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TRIB Yearly Revenue VS EstimatesTRIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
TRIB Yearly EPS VS EstimatesTRIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -5 -10

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRIB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TRIB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRIB Price Earnings VS Forward Price EarningsTRIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRIB Per share dataTRIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.51%
EPS Next 3Y5.36%

0

5. Dividend

5.1 Amount

No dividends for TRIB!.
Industry RankSector Rank
Dividend Yield N/A

TRINITY BIOTECH PLC-SPON ADR

NASDAQ:TRIB (4/25/2025, 8:00:01 PM)

After market: 0.72 +0.01 (+1.69%)

0.708

+0.07 (+10.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-15 2024-11-15/bmo
Earnings (Next)N/A N/A
Inst Owners4.63%
Inst Owner Change-75.72%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap13.59M
Analysts85.71
Price TargetN/A
Short Float %3.51%
Short Ratio2.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.4%
Min EPS beat(2)-7.69%
Max EPS beat(2)16.49%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.68%
Min Revenue beat(2)-9.97%
Max Revenue beat(2)-1.38%
Revenue beat(4)0
Avg Revenue beat(4)-8.38%
Min Revenue beat(4)-12.24%
Max Revenue beat(4)-1.38%
Revenue beat(8)1
Avg Revenue beat(8)-8.64%
Revenue beat(12)1
Avg Revenue beat(12)-16.66%
Revenue beat(16)4
Avg Revenue beat(16)-11.95%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.81%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.23
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.28
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.81
FCFYN/A
OCF(TTM)-0.38
OCFYN/A
SpS3.08
BVpS-1.37
TBVpS-3.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 35.74%
FCFM N/A
ROA(3y)-28.07%
ROA(5y)-22.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.44%
GM growth 5Y-4.34%
F-Score4
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 431.9%
Cap/Sales 13.9%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.64
Quick Ratio 0.87
Altman-Z -0.43
F-Score4
WACC9.61%
ROIC/WACCN/A
Cap/Depr(3y)241.7%
Cap/Depr(5y)259.74%
Cap/Sales(3y)8.34%
Cap/Sales(5y)9.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.75%
EPS Next Y-194.92%
EPS Next 2Y-23.51%
EPS Next 3Y5.36%
EPS Next 5YN/A
Revenue 1Y (TTM)-0.01%
Revenue growth 3Y-17.71%
Revenue growth 5Y-10.15%
Sales Q2Q%3.24%
Revenue Next Year6.69%
Revenue Next 2Y8.4%
Revenue Next 3Y9.95%
Revenue Next 5YN/A
EBIT growth 1Y27.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-256.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-357.13%
OCF growth 3YN/A
OCF growth 5YN/A